Cell and gene therapies are quickly reaching an inflection point, showing great promise for the future of patient care. At GE Healthcare’s Cell Therapy Technologies, we strive to be at the forefront of this revolution by providing the right combination of customized tools, analytics, and support, while helping to standardize and optimize scale-out manufacturing technologies. Together we hope to realize the promise of these revolutionary new medicines and bring them into mainstream clinical use.
Akron Biotech is an innovative biotechnology company with a strategic focus on supplying GMP-qualified raw materials and services to the regenerative medicine industry. Akron manufactures a range of products for cell therapy discovery, development, and commercialization. These products include growth factors, sera and purified proteins, custom-made cell culture media, tailored scaffolds with biomaterials, and proprietary cryopreservation formulations.
Be The Match BioTherapiesSM partners with organizations pursuing new life-saving treatments in cellular therapy at any stage of development—from discovery through commercialization. We have unparalleled experience in cell sourcing and collection, cell supply chain with personalized patient management, immunogenetics and bioinformatics, research and regulatory compliance. Discover our solutions:
As one of the largest healthcare supply chains in North America, we are Essential to Care™. And with connections across the continuum of care, we continue to make critical moves necessary to compete and create value in today’s dynamic healthcare environment.
Cryoport is the leading provider of cryogenic logistics solutions for temperature-sensitive life sciences materials. With proprietary Cryoport Express® liquid nitrogen dry vapor shippers and packaging, innovative Cryoportal™ technology and cold chain logistics expertise, Cryoport is the preferred cryogenic logistics partner for the world’s largest shipping companies
IntelliCyt’s iQue Screener platform is an integrated instrument, software, and reagent solution that offers rapid, multiplexed analysis of cell and bead-based samples in 96, 384, and 1536 well plates. The iQue Screener’s proprietary sampling technology uniquely enables rapid assessment of cells in suspension, such as those found in blood and bone marrow, by miniaturizing the assay format, which conserves precious samples for further analysis. Read more here.
For over 25 years, Lonza has been helping emerging biotech and pharmaceutical companies improve and advance their products. Whether you are in the early stages of clinical development or providing commercial product to patients around the globe, Lonza supplies complete development services, industry-leading manufacturing, and broad technology platforms that enable products to reach their full potential.
Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. We provide products and services that advance biomedical research and cellular therapy. Honoring this mission drives our commitment to support the translation of basic research into therapy in the areas of immunology, cancer, neuroscience and stem cell biology. We innovate products that address sample preparation, separation of cells and their analysis, and that advance the concept of cellular therapy.
Oxford Genetics is a synthetic biology company specialising in DNA design, protein expression optimisation and cell line development technologies and services. These systems are built upon a modular DNA expression system (SnapFastTM) that allows us to rapidly create complex DNA expression systems expressing any genes of interest with maximal protein expresion levels.
Promab Biotechnologies provides a completely comprehensive CAR-T pre-clinical package, allowing for accelerated proof-of-concept, and IP positioning, beginning with the generation of a mouse, rabbit, or human (library) monoclonal antibody, or with the synthesis and cloning of existing antibody sequence into a CAR expression construct. Promab is positioned to explore collaboration with partners in order to rapidly expand clinical targets. Read more here.